TTX siLIN28b
Alternative Names: TTX-siLIN28bLatest Information Update: 14 Jul 2021
At a glance
- Originator TransCode Therapeutics
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Gene silencing; RNA-binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Pancreatic cancer
Most Recent Events
- 09 Jul 2021 Preclinical trials in Breast cancer in USA (TransCode Therapeutics pipeline, July 2021 (9329380)
- 09 Jul 2021 Preclinical trials in Colorectal cancer in USA (TransCode Therapeutics pipeline, July 2021 (9329380)
- 09 Jul 2021 Preclinical trials in Gastric cancer in USA (TransCode Therapeutics pipeline, July 2021 (9329380)